HKEX: 6996
2026 Interim report
Earlier from Antengene
- Next Day Disclosure Return
- Antengene Announces First Patient Dosed in Pivotal Phase III CLINCH-3 Study of ATG-022
- Antengene Publishes Preclinical Research Paper on CD73 Small Molecule Inhibitor ATG-037 Combined with Selinexor in Cancer Gene Therapy
- Antengene Receives Clinical Trial Approval in Australia for Phase I ATTRACT Study of ATG-201 (CD19 x CD3 TCE) in B Cell-related Autoimmune Diseases